Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national database analysis

Affiliations

¹ John Sealy School of Medicine, University of Texas Medical Branch, Galveston, Texas.
² John Sealy School of Medicine, University of Texas Medical Branch, Galveston, Texas; Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.
³ Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.
⁴ Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY.
⁵ Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas.
⁶ Department of Dermatology, University of Texas Medical Branch, Galveston, Texas.
⁷ Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: nicholas.gulati@mssm.edu.

David Garate et al. J Allergy Clin Immunol Pract. 2025 Mar.

. 2025 Mar;13(3):698-701.e1.

doi: 10.1016/j.jaip.2024.11.015. Epub 2024 Nov 28.

¹ John Sealy School of Medicine, University of Texas Medical Branch, Galveston, Texas.
² John Sealy School of Medicine, University of Texas Medical Branch, Galveston, Texas; Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.
³ Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.
⁴ Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY.
⁵ Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas.
⁶ Department of Dermatology, University of Texas Medical Branch, Galveston, Texas.
⁷ Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: nicholas.gulati@mssm.edu.

No abstract available

LinkOut - more resources